Evidence map›Paper›PMID 40155505›Full record

ArticleScientific reports2025

Revisiting eye blink in Parkinson's disease.

Varsha Vasudevan, Quentin Salardaine, Sophie Rivaud-Péchoux, Emma Biondetti, Nicolas Villain, Stephane Lehericy, Marie Vidailhet, Pierre Pouget

Abstract read
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Varsha VasudevanINSERM U1127, CNRS UMR7225, UM75, Movement Investigation and Therapeutics Team, Paris Brain Institute, ICM, Sorbonne Université, Paris, France. varsha.vd.gupta@gmail.com.
Quentin SalardaineINSERM U1127, CNRS UMR7225, UM75, Movement Investigation and Therapeutics Team, Paris Brain Institute, ICM, Sorbonne Université, Paris, France.
Sophie Rivaud-PéchouxINSERM U1127, CNRS UMR7225, UM75, Movement Investigation and Therapeutics Team, Paris Brain Institute, ICM, Sorbonne Université, Paris, France.
Emma BiondettiDepartment of Neurosciences, Imaging, and Clinical Sciences, University 'G. D'Annunzio' of Chieti-Pescara, Chieti, Italy.
Nicolas VillainINSERM U1127, CNRS UMR7225, UM75, Movement Investigation and Therapeutics Team, Paris Brain Institute, ICM, Sorbonne Université, Paris, France.
Stephane LehericyINSERM U1127, CNRS UMR7225, UM75, Movement Investigation and Therapeutics Team, Paris Brain Institute, ICM, Sorbonne Université, Paris, France.
Marie VidailhetINSERM U1127, CNRS UMR7225, UM75, Movement Investigation and Therapeutics Team, Paris Brain Institute, ICM, Sorbonne Université, Paris, France.
Pierre PougetINSERM U1127, CNRS UMR7225, UM75, Movement Investigation and Therapeutics Team, Paris Brain Institute, ICM, Sorbonne Université, Paris, France. pierre.pouget@gmail.com.

Funding

European Union's Horizon Europe research and innovation program Marie Skłodowska-Curie grant agreement No 101066055 - acronym HERMES
6 · The paper itself

Abstract

Spontaneous blinking is a rapid and unconscious type of blinking that has been linked to several cognitive processes. Blink rate has been established as a reliable measure of cognitive processing and a predictor of dopamine-related cognitive function. Patients with Parkinson's disease (PD) have a reduced spontaneous blink rate. In this study, we propose an additional measure of blink characteristic, namely blink duration, and evaluate its alteration in a large cohort of 107 patients with PD. We also investigate the relationship between blink rate and blink duration and disease characteristics such as severity and dopaminergic neuronal loss. The results show that the blink rate is reduced, and blink duration is increased in patients compared to healthy controls. Blink rate is related to motor deficit severity and significantly correlated with dopamine depletion (dopamine transporter striatal binding ratio). Conversely, blink duration is related to non-motor aspects such as sleepiness. These findings highlight the potential of blink as a distinguishing feature of Parkinson's disease, underscoring the importance of incorporating blink assessments into standardized oculomotor testing protocols for PD.

Indexed as

BlinkingParkinson DiseaseAgedCase-Control StudiesDopamineDopamine Plasma Membrane Transport ProteinsDopaminergic NeuronsFemaleHumansMaleMiddle AgedDopamineDopamine Plasma Membrane Transport Proteins

Identifiers

PMID40155505
PMCPMC11953315

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.